Estelamari Rodriguez, MD, MPH

Estelamari Rodriguez, MD, MPH, is associate director of Community Outreach – Thoracic Oncology at Sylvester Comprehensive Cancer Center.

Articles

Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC

February 2nd 2025

Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.

Overcoming Disparities in Cancer Care

January 6th 2025

Estelamari Rodriguez, MD, MPH, discusses how to overcome disparities in cancer care.

Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLC

February 3rd 2024

Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.

Uncommon EGFR Mutations in NSCLC: Future Directions in Care

July 21st 2023

Closing out their discussion on uncommon EGFR mutations in non–small cell lung cancer, Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, consider how the treatment paradigm will continue to evolve.

Uncommon EGFR Mutations in NSCLC: Real-World Selection and Use of Novel Agents

July 21st 2023

Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, reflect on their experience managing real-world patients with uncommon EGFR mutations in non–small cell lung cancer.

Treatment Options for Patients with Uncommon EGFR Mutations in NSCLC

July 14th 2023

Focused discussion on uncommon EGFR mutations in non–small cell lung cancer and concurrent treatment options in this setting.

Refining EGFR Classifications and Impact on Treatment for NSCLC

July 14th 2023

Experts Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, highlight current understandings of EGFR mutation classifications in the context of non–small cell lung cancer.

Overcoming Barriers to Molecular Testing in NSCLC With Multidisciplinary Care

July 7th 2023

A brief discussion on key barriers to molecular testing in non–small cell lung cancer and how multidisciplinary care plays a role in addressing these hurdles.

NSCLC: Selecting a Molecular Testing Assay and Interpreting Results

July 7th 2023

Shared perspective on the armamentarium of molecular testing assays in non–small cell lung cancer and how results can be best interpreted when selecting treatment.

Evolving Field of Molecular Testing in Non–Small Cell Lung Cancer

June 30th 2023

Expert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.

Dr Rodriguez on TKIs in Lung Cancers With Uncommon EGFR Mutations

April 19th 2023

Estelamari Rodriguez, MD, MPH, discusses the benefits of the TKIs afatinib and osimertinib in patients with lung cancer with uncommon EGFR mutations.

Dr. Rodriguez on the Role of Immunotherapy in ES-SCLC

September 16th 2021

Estelamari Rodriguez, MD, MPH, discusses the role of immunotherapy in extensive-stage small cell lung cancer.

x